Cookies help us deliver our services. By using our services, you agree to our use of cookies.
Learn more
OK
Skip to main content (Press Enter).
Sign In
Skip auxiliary navigation (Press Enter).
Contact Us
Skip main navigation (Press Enter).
Toggle navigation
Search Options
About
What is the AMS
AMS International Scientific Committee
AMS North America Scientific Committee
AMS Educational Executive Committee
AMS Ambassadors
Certifications and Educational Credits
Upcoming Events
Videos & Webinars
International Events
Become a Speaker
Videos On Demand
Education 365
Preview AMS TV
Features
AMS Features
News & Publications
AMS Bookstore
Blogs
Industry
Industry Partners
Become a Sponsor
Features
Blogs
Blog Viewer
Blogs
Vismodegib (ERIVEDGE) pregnancy prevention programme: assessment of risk awareness
By
- AMS
posted
Jun 01, 2020 01:22 PM
0
Recommend
.
0 comments
0 views
Permalink
Related Content
Secukinumab during pregnancy: a case report and review of literature
- AMS
Added Apr 13, 2020
Blog Entry
The effectiveness of vismodegib in patients with advanced periocular basal cell carcinoma: a case series of 13 patients
- AMS
Added Jun 02, 2020
Blog Entry
Assessment of dermatologist–patient gender concordance among medicare beneficiaries
- AMS
Added Jul 17, 2020
Blog Entry
Hyperhidrosis and the risk of being treated for skin infections
- AMS
Added Jul 05, 2021
Blog Entry
Value of silicone gel in prevention of cobblestoning following punch minigrafting in vitiligo
- AMS
Added Apr 13, 2020
Blog Entry
© 2022 AMS, Aesthetic Multispecialty Society. All Rights Reserved.
Powered by Higher Logic